Original Research
Accepted on 07 Apr 2025
Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2025.1557641
- Frontiers in Hematology
- Blood Cancer
- Articles
Type at least 3 characters
57 articles
Clinical Trial
Accepted on 21 Mar 2025
Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2025.1554764
Review
Published on 21 Mar 2025
Exercise and diet studies among patients living with multiple myeloma: current evidence and considerations of patient preferences
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2025.1550681
- 694 views
Case Report
Published on 04 Mar 2025
Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemia
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2025.1552200
- 551 views
Review
Published on 03 Mar 2025
Abnormalities of primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, the coagulation system, and the bone marrow microenvironment
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2025.1435193
- 557 views
Case Report
Published on 26 Feb 2025
Acquired von Willebrand disease associated with smoldering multiple myeloma and hereditary hemorrhagic telangiectasia successfully treated with daratumumab, pomalidomide, and dexamethasone: hitting three birds with one stone? – case report
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2025.1499500
- 405 views
Original Research
Published on 21 Feb 2025
Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2025.1521017
- 292 views
Original Research
Published on 21 Jan 2025
Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1502166
- 1,837 views
Case Report
Published on 16 Jan 2025
Case report: VEXAS syndrome: first documented cases in Latin America
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1501337
- 371 views
Case Report
Published on 10 Jan 2025
Case report: A decade-long journey with cyclic thrombocytopenia
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1482891
- 404 views
Mini Review
Published on 24 Dec 2024
Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1504327
- 632 views
Case Report
Published on 17 Dec 2024
A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1463487
- 500 views
Case Report
Published on 12 Dec 2024
Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1508463
- 306 views
Study Protocol
Published on 06 Dec 2024
Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1436845
- 815 views
Original Research
Published on 05 Dec 2024
Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1480120
- 545 views
Original Research
Published on 22 Nov 2024
Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia
in Blood Cancer
Frontiers in Hematology
doi 10.3389/frhem.2024.1492680
- 368 views